{"entity":{"id":"nct04501523","kind":"trial","name":"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC","aka":["Apollo"],"tldr":"A phase 2 trial of tislelizumab and capecitabine in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting.","summary":"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC is a phase 2, randomised interventional study registered as NCT04501523 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with a registry enrolment figure of 460 participants, started 2020-08-03 and due to reach its primary completion in 2027-08. Interventions recorded: Tislelizumab; capecitabine. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-) invasive breast cancer, clinical stage II-III at diagnosis (AJCC 6th edition) based on initial evaluation by physical examination and/or breast imaging prior to study registration\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04501523","url":"https://clinicaltrials.gov/study/NCT04501523"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["tislelizumab","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04501523","phase":"2","setting":"A Prospective, Phase II Trial Using Circulating Tumor DNA to Initiate Post-operation Boost Therapy After Neoadjuvant Chemotherapy in Triple-negative Breast Cancer","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","participation":[{"nct":"NCT04501523","source":"https://clinicaltrials.gov/study/NCT04501523","fetchedAt":"2026-10-07T16:53:21.208Z","studySha256":"bf3b6ede6366e192d9e810e1eb4900b3287188526a921bca8e829c44bf8c6fe1","overallStatus":"RECRUITING","lastUpdatePosted":"2023-02-21","leadSponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":460,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2020-08-03","startedType":"actual","enrolled":460,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04501523/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}